Replies to post #93 on Ardelyx Inc (ARDX)

[Amatuer17]

Agree - it is Monotherapy and if approved will automatically become Standard of Care.
The co does not have marketing capability so it will become takeover target easily


Also this is good news today on - 2 undisclosed indications

to advance two of Ardelyx's ongoing research programs focused on the identification and design of compounds to two undisclosed targets.

https://finance.yahoo.com/news/ardelyx-kyowa-kirin-expand-partnership-230000274.html